InstalabLoading...
InstalabLoading...
If you want a window into the part of your immune system that produces antibodies, this is one of the more direct readouts available. CD38+ IgM- cells are the mature, class-switched B cells and plasmablasts that pump out antibodies during infection, after vaccination, and in autoimmune flares.
This is a research-grade flow cytometry measurement, not a routine blood test. It is most useful for people tracking immune activation in specific clinical contexts, such as autoimmune disease, transplant monitoring, or B-cell malignancies.
CD38+ IgM- (CD38 positive, surface IgM negative) describes a specific population of B-lineage cells found by flow cytometry, a lab technique that uses lasers and antibody tags to count and sort cells based on the proteins on their surface. These cells carry the CD38 protein, a surface molecule that acts both as an enzyme and an activation signal, but they have lost surface IgM (immunoglobulin M, the first antibody type a B cell makes).
In practice, this combination identifies B cells that have already gone through class switching, meaning they have moved past the IgM stage and are now producing other antibody types like IgG. The CD38+ IgM- pool is dominated by plasmablasts and plasma cells, the body's antibody-secreting workhorses, along with class-switched memory B cells. When this population is high, your body is doing a lot of antibody production. When it shifts in unexpected ways, it can signal something off in your humoral immunity.
CD38 itself is more than a label. It is an ectoenzyme, a protein on the cell surface that breaks down NAD+ (a molecule cells use for energy and signaling) and helps regulate calcium signaling inside immune cells. It also acts as a receptor that participates in cell adhesion, migration, and cytokine release.
This dual role explains why CD38 shows up across many immune contexts. CD38 levels are very high on plasmablasts and plasma cells, intermediate on transitional B cells, and lower on naive and memory subsets. Activated and exhausted T cells also express CD38, which is why this marker is studied in viral infections and autoimmune disease.
In systemic sclerosis (a connective tissue disease), CD38 expression is increased on peripheral blood plasmablasts and plasma cells. In systemic lupus erythematosus, CD38 is elevated across multiple immune cell subsets, including marginal zone-like B cells and plasma cells, with IgG+ and IgM+ plasmablasts expressing higher CD38 than IgA+ cells.
What this means for you: a high CD38+ IgM- count in the context of autoimmune symptoms suggests active antibody-mediated immunity. It is also why anti-CD38 drugs like daratumumab are being studied in autoimmune disease. A randomized phase Ib/IIa trial of the anti-CD38 antibody CM313 in 40 lupus patients showed a manageable safety profile and clinical efficacy at 8 and 16 mg/kg doses.
In kidney transplant recipients, IgM-/c0 CD38 high CD27 high plasmablasts drop sharply early after transplant, then gradually repopulate. Their kinetics mirror transitional B cell recovery, and abnormal patterns track with rejection risk. In one study of 67 kidney transplant recipients with chronic active antibody-mediated rejection, CD38+ B cell infiltration above 93 cells per square millimeter was associated with poor graft survival.
What this means for you: if you are managing a transplant or considering one, plasmablast dynamics give a more direct read on the cells driving rejection than standard creatinine-based monitoring.
In chronic lymphocytic leukemia (CLL), the percentage of CD38+ leukemic B cells is one of the strongest prognostic markers available. Across multiple cohorts, patients with 30 percent or more CD38+ cells have unmutated immunoglobulin genes, need more chemotherapy, and have shorter survival. Patients below that threshold often have mutated genes, need little or no treatment, and live longer.
In diffuse large B-cell lymphoma, high CD38 expression is an independent adverse prognostic factor for progression-free and overall survival across 137 patients. In multiple myeloma, plasma cells are CD38+ and CD138+, which is why anti-CD38 antibodies like daratumumab are now standard therapy. A meta-analysis of newly diagnosed multiple myeloma patients found that anti-CD38 monoclonal antibody-based therapy significantly improved minimal residual disease status and progression-free survival compared with standard therapy.
In COVID-19, persistently high HLA-DR+ CD38 high CD8+ T cells are associated with systemic inflammation, tissue injury, and worse clinical outcomes. In a study of 823 hospitalized COVID-19 patients, a higher proportion of activated CD8+ CD38+ cells was associated with worse clinical outcomes. In HIV, the percentage of CD8+ CD38+ T cells independently predicts progression to AIDS, separate from CD4 count.
What this means for you: CD38 on T cells is a marker of chronic immune activation, which carries its own long-term health costs. This is why some longevity-minded people track activation markers as part of broader inflammation panels.
The story flips somewhat in solid tumors. In hepatocellular carcinoma, a higher proportion of CD38+ cells in the tumor microenvironment predicts better response to checkpoint inhibitors and longer overall survival. In epithelial ovarian cancer (389 patients) and breast cancer, higher CD38 is also linked to improved survival, likely reflecting stronger antitumor immunity.
This isn't a simple high-equals-bad or low-equals-good marker. It is a phenotype indicator, and what counts as a healthy CD38+ IgM- level depends entirely on the clinical context. The same number can mean robust vaccine response in a healthy person, an autoimmune flare in someone with lupus, or a tumor responding to immunotherapy.
There are no widely standardized reference intervals for CD38+ IgM- cells in healthy adults. The values that exist come from disease cohorts, not general population norms, and flow cytometry results vary substantially based on the lab, the antibody clones used, and the gating strategy.
For CLL specifically, the most widely used cutpoint is 30 percent CD38+ leukemic cells, with some studies using 20 percent. These are illustrative orientation values from disease research, not health targets. They should not be applied to anyone without a CLL diagnosis.
| Context | CD38+ Threshold | What It Suggests |
|---|---|---|
| CLL leukemic cells | Below 20 percent | Lower-risk, more indolent disease course |
| CLL leukemic cells | 20 to 30 percent | Intermediate prognostic risk |
| CLL leukemic cells | 30 percent or higher | More aggressive disease, shorter survival |
Source: Damle et al., Blood 1999; Ibrahim et al., Blood 2001; Hamblin et al., Blood 2002. These thresholds apply only to leukemic cells in diagnosed CLL and have no validated meaning in healthy adults.
For tracking purposes, compare your results within the same lab over time using the same flow panel. A single absolute number means much less than a trend.
CD38 expression on B cells can shift during the course of disease. In CLL, CD38 levels can fluctuate over time, which is why serial measurement matters more than a single snapshot. The same is true in autoimmune disease, where plasmablast counts rise and fall with flares and remissions.
Get a baseline reading, then retest in 3 to 6 months if you are starting a treatment that targets B cells (like rituximab or daratumumab) or making a major change in immunosuppression. After that, annual testing is reasonable for ongoing monitoring in a stable clinical context.
The trend matters more than any individual value. A single elevated reading without a clinical context is hard to interpret. Two or three readings over time, in the context of how you feel and what your other labs show, give a much clearer picture.
Several factors can shift CD38+ IgM- counts without indicating any underlying disease change. Knowing them prevents over-reaction to a single number.
This is a specialty test, and the decision pathway depends entirely on why you ordered it. If you are tracking autoimmune disease, an unexpected rise in plasmablasts alongside symptom flare is worth discussing with a rheumatologist, particularly when considering B-cell-targeted therapy.
If you are managing a transplant, a sustained rise in CD38+ B cell infiltration warrants a conversation with your transplant team about the possibility of antibody-mediated rejection. If you have CLL or are being evaluated for a B-cell cancer, CD38 results should be interpreted alongside immunoglobulin gene mutation status and ZAP-70 by a hematologist.
For someone without a known condition, an unusual result is most often a flag to look at companion markers like immunoglobulin levels (IgG, IgA, IgM), inflammation markers, and a full T and B cell panel before drawing conclusions.
Evidence-backed interventions that affect your CD38+ IgM- level
CD38+ IgM- is best interpreted alongside these tests.